Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
28.8M
-
Shares change
-
+5.68M
-
Total reported value, excl. options
-
$29.9M
-
Value change
-
+$5.25M
-
Number of buys
-
21
-
Number of sells
-
-32
-
Price
-
$1.04
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2020
72 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q1 2020.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.8M shares
of 108M outstanding shares and own 26.58% of the company stock.
Largest 10 shareholders include MFN Partners Management, LP (4M shares), RENAISSANCE TECHNOLOGIES LLC (3.18M shares), Endurant Capital Management LP (2.62M shares), Samsara BioCapital, LLC (2.61M shares), EcoR1 Capital, LLC (2.09M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), Sofinnova Investments, Inc. (1.91M shares), Vivo Capital, LLC (1.65M shares), Rock Springs Capital Management LP (1.6M shares), and Parkman Healthcare Partners LLC (1.54M shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.